Editas Medicine I…
USUSDEditas Medicine Inc (US:EDIT) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- editasmedicine.com
- Relations avec les investisseurs
- ir.editasmedicine.com/investor-relations
- Secteur
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siège social
- Cambridge, United States
- PDG
- Dr. Gilmore O'Neill M.D.
- Employés
- 87
- Fondée
- 2013
- Actions en circulation
- 153.58 M au 2026-07-31
- Flottant
- 115.49 M
- Capitalisation boursière
- 397.77 M USD
- Initiés
- 0.18%
- Investisseurs institutionnels
- 79.29%
- Secteur d'activité (SIC)
- Biological Products, (No Diagnostic Substances)
- ISIN
- US28106W1036
- LEI
- 5299000AON4Q9NT2JE42
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Dividendes
Aucun versement de dividendes n'a été trouvé (vérifié le 09.10.2026). L'entreprise ne verse probablement pas de dividendes.
Actualités de cette semaine
Pas encore d'actualités du site de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| TCG Crossover Management… | 7.23% | 11.11 M | 2026-06-30 |
| Blackrock Inc. | 6.9% | 10.59 M | 2026-06-30 |
| Commodore Capital Lp | 5.79% | 8.89 M | 2026-06-30 |
| RA Capital Management, L… | 5.79% | 8.89 M | 2026-06-30 |
| Adar1 Capital Management… | 5.79% | 8.89 M | 2026-06-30 |
| Vanguard Capital Managem… | 4% | 6.14 M | 2026-06-30 |
| Paradigm Biocapital Advi… | 3.64% | 5.59 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.18% | 4.89 M | 2026-06-30 |
| Opaleye Management Inc. | 2.51% | 3.86 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.34% | 3.6 M | 2026-06-30 |
| Woodline Partners LP | 2.32% | 3.56 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.68% | 2.58 M | 2026-07-31 |
| VANGUARD HORIZON FUNDS-V… | 1.32% | 2.03 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.72% | 1.1 M | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.71% | 1.09 M | 2026-07-31 |
| iShares Trust-iShares Bi… | 0.69% | 1.06 M | 2026-08-31 |
| iShares Trust-iShares Ru… | 0.55% | 850 485 | 2026-08-31 |
| Fidelity Concord Street… | 0.34% | 522 584 | 2026-07-31 |
| VANGUARD SCOTTSDALE FUND… | 0.33% | 505 306 | 2026-05-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.31% | 476 309 | 2026-05-31 |
| O NEILL GILMORE NEIL (Ch… | ≈0.16% | 243 189 | 2026-09-03 |
| MEI BAISONG (Officer) | ≈0.09% | 133 354 | 2024-12-03 |
| LUCERA ERICK J. (Chief F… | ≈0.07% | 112 720 | 2025-03-04 |
| BURKLY LINDA (Officer) | ≈0.04% | 61 660 | 2026-09-03 |
| PARISON AMY (Chief Finan… | ≈0.01% | 13 839 | 2026-09-03 |
